



NDA 20692/S-045

SUPPLEMENT APPROVAL

GlaxoSmithKline
1250 South Collegeville Road
PO Box 5089, Mail Code UP4400
Collegeville, PA 19426

Attention: Linda Rebar
Director, Global Regulatory Affairs

Dear Ms. Rebar:

Please refer to your Supplemental New Drug Application (sNDA) dated and received April 1, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Serevent Diskus (salmeterol xinafoate inhalation powder).

This Prior Approval supplemental new drug application provides updates and corrections to the U.S. Prescribing Information, Medication Guide, and Instructions for Use that include the following:

- Adding the number of blisters contained inside the DISKUS to the front label of the device for improved clarity,
- Updating the graphic of the DISKUS on the carton for consistency with the above mentioned revised label of the device,
- Adding "INSTITUTIONAL PACK" to the back of the Institutional Pack's device label,
- Updating the PLR format to FDA's current standard,
- Miscellaneous revisions for consistency with labeling changes approved for Breo Ellipta (fluticasone furoate/vilanterol inhalation powder) NDA 204275/S-001 on April 30, 2015, and for Anoro Ellipta (umeclidinium/vilanterol inhalation powder) NDA 203975/S-003 on February 24, 2016,
- Converting the Medication Guide to the box format currently being implemented by FDA, and
- Updating figures in the Medication Guide that feature the front label of the DISKUS.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 20692/S-045.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your supplemental application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Christine Ford, Regulatory Project Manager, at (301) 796-3420.

Sincerely,

{See appended electronic signature page}

Sally Seymour, M.D.
Deputy Director of Safety
Division of Pulmonary, Allergy, and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SALLY M SEYMOUR
09/30/2016